Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity RatioInvested CapitalReturn on AssetsReturn on Capital Employed

Cardiol Therapeutics (CRDL) Invested Capital (2020 - 2026)

Cardiol Therapeutics filings provide 3 years of Invested Capital readings, the most recent being $38.8 million for Q4 2022.

  • On a quarterly basis, Invested Capital fell 39.83% to $38.8 million in Q4 2022 year-over-year; TTM through Dec 2022 was $38.8 million, a 39.83% decrease, with the full-year FY2022 number at $38.8 million, down 39.83% from a year prior.
  • Invested Capital hit $38.8 million in Q4 2022 for Cardiol Therapeutics, up from $1.5 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $64.4 million in Q4 2021 to a low of $1.5 million in Q3 2022.
  • Median Invested Capital over the past 3 years was $6.9 million (2022), compared with a mean of $20.2 million.
  • Biggest five-year swings in Invested Capital: soared 532.97% in 2021 and later plummeted 39.83% in 2022.
  • Cardiol Therapeutics' Invested Capital stood at $10.2 million in 2020, then soared by 532.97% to $64.4 million in 2021, then plummeted by 39.83% to $38.8 million in 2022.
  • The last three reported values for Invested Capital were $38.8 million (Q4 2022), $1.5 million (Q3 2022), and $2.9 million (Q2 2022) per Business Quant data.